What is the usage and dosage of Eflornithine for treating African trypanosomiasis and hirsutism in women?

Eflornithine: Usage and Dosage

African Trypanosomiasis (Sleeping Sickness)

Eflornithine is effective for treating West African trypanosomiasis (T.b. gambiense) but has limited efficacy against East African trypanosomiasis (T.b. rhodesiense) due to innate parasite resistance. 1, 2

Treatment Regimen for T.b. gambiense

• Standard dosing: 100 mg/kg body weight intravenously every 6 hours for 14 days as short infusions 3
• Pediatric dosing: 150 mg/kg body weight every 6 hours for 14 days 3
• Total daily dose: 400 mg/kg/day divided into four doses 4

Clinical Considerations for Trypanosomiasis Treatment

• Eflornithine is primarily used as a backup treatment for melarsoprol-refractory T.b. gambiense cases 3
• Cerebrospinal fluid levels must exceed 50 μmol/L to achieve consistent parasite clearance 3
• The drug has a trypanostatic (not trypanocidal) mechanism, making it slower-acting than alternatives 3
• More than 80% of the drug is eliminated unchanged through renal clearance 3

Limitations in Rhodesiense HAT

• Eflornithine has limited efficacy against T.b. rhodesiense due to higher ornithine decarboxylase turnover in this parasite subspecies 3
• Current WHO guidelines (2025) recommend fexinidazole or other agents as first-line therapy for rhodesiense HAT, not eflornithine 1, 2

Adverse Effects in Trypanosomiasis Treatment

High-dose intravenous eflornithine (400 mg/kg/day) causes significant toxicity 4, 3:

• Neurological: Seizures/convulsions (7%), hearing impairment (5%) 3
• Gastrointestinal: Nausea, vomiting, diarrhea (10-39%) 3
• Hematological: Anemia, leukopenia, thrombocytopenia (25-50%) 3
• Dermatological: Alopecia (5-10%) 3
• Other: Facial swelling, headache, weakness, dizziness 4

These adverse events are generally reversible after discontinuation and increase with treatment duration and disease severity 3

---

Hirsutism in Women

Topical eflornithine 13.9% cream is FDA-approved for reducing unwanted facial hair in women and should be used as adjunctive therapy with systemic treatments or laser therapy, not as monotherapy for moderate-to-severe hirsutism. 5, 6, 7

Dosing and Application

• Apply 13.9% cream (marketed as VANIQA) twice daily to affected facial areas 4
• Apply a thin layer to clean, dry skin at least 8 hours apart 4
• Patients may apply cosmetics or sunscreen at least 5 minutes after application 4
• Treatment must be continuous; hair growth returns to baseline within 8 weeks of discontinuation 8

Efficacy Timeline

• Initial improvement visible after 4-8 weeks of twice-daily application 8
• Optimal results require 24 weeks of continuous treatment 8
• At 24 weeks, 58% of patients show at least some improvement versus 34% with placebo 8
• 32% achieve marked improvement versus 8% with placebo 8

Pharmacokinetics and Safety

• Percutaneous absorption is less than 1% of applied dose under normal use conditions 4
• Steady-state plasma concentrations (Cmax ~10 ng/mL) are approximately 100-fold lower than oral dosing 4
• Plasma half-life is approximately 8 hours with steady state reached within 4 days 4
• The drug is not metabolized and is excreted unchanged in urine 4

Adverse Effects (Topical Use)

• Most common: Burning, stinging, or tingling at application site (markedly more common than placebo) 8
• Other dermatological reactions include acne, pseudofolliculitis barbae, dry skin, pruritus, erythema, and rash 8
• Systemic toxicity is not expected given minimal absorption 4

Treatment Algorithm for Hirsutism

First-line approach: 5, 7

1. Combined oral contraceptives (COCs) with antiandrogenic activity - avoid androgenic progestins like norethisterone or levonorgestrel 5
2. Add topical eflornithine as adjunctive therapy for enhanced cosmetic benefit 6, 7
3. Consider laser therapy (alexandrite or diode lasers) for permanent hair reduction 7

Second-line approach (if inadequate response after 6-9 months): 6, 7

• Add antiandrogen therapy: spironolactone (first-line), finasteride or cyproterone acetate (second-line) 7
• Continue topical eflornithine as adjunct 6, 7

Key Clinical Pitfalls

• Do not use topical eflornithine as monotherapy for moderate-to-severe hirsutism - it is only appropriate as adjunctive treatment 6, 7
• Do not expect rapid results - minimum 6 months required for pharmacotherapy benefit 7
• Warn patients about hair regrowth - lifelong treatment often necessary for sustained benefit 7
• Avoid in pregnancy - eflornithine arrests embryonic development in animal studies 3
• Excretion into breast milk is unknown 3

Special Populations

• For adolescents with PCOS-related hirsutism and endocrine comorbidities, early intervention with antiandrogens may be beneficial 5
• Women with insulin resistance and PCOS may benefit from metformin for metabolic abnormalities, but insulin sensitizers alone do not significantly improve hirsutism 7
• Weight loss of 5% can improve metabolic and reproductive abnormalities in obese women with PCOS 5